As of 2025-11-13, the Intrinsic Value of GlaxoSmithKline PLC (GSK.L) is 1,453.39 GBP. This GSK.L valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 1,823.50 GBP, the upside of GlaxoSmithKline PLC is -20.30%.
The range of the Intrinsic Value is 1,097.79 - 2,085.99 GBP
Based on its market price of 1,823.50 GBP and our intrinsic valuation, GlaxoSmithKline PLC (GSK.L) is overvalued by 20.30%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 1,097.79 - 2,085.99 | 1,453.39 | -20.3% |
| DCF (Growth 10y) | 1,245.43 - 2,180.26 | 1,585.55 | -13.0% |
| DCF (EBITDA 5y) | 1,526.89 - 1,983.92 | 1,807.88 | -0.9% |
| DCF (EBITDA 10y) | 1,577.71 - 2,137.34 | 1,885.33 | 3.4% |
| Fair Value | 3,390.40 - 3,390.40 | 3,390.40 | 85.93% |
| P/E | 1,748.20 - 2,866.92 | 2,203.39 | 20.8% |
| EV/EBITDA | 2,088.80 - 2,679.90 | 2,380.41 | 30.5% |
| EPV | 1,070.29 - 1,464.87 | 1,267.58 | -30.5% |
| DDM - Stable | 818.61 - 1,809.75 | 1,314.18 | -27.9% |
| DDM - Multi | 606.40 - 1,000.47 | 751.62 | -58.8% |
| Market Cap (mil) | 73,872.72 |
| Beta | 1.01 |
| Outstanding shares (mil) | 40.51 |
| Enterprise Value (mil) | 88,326.72 |
| Market risk premium | 5.98% |
| Cost of Equity | 11.17% |
| Cost of Debt | 4.29% |
| WACC | 9.76% |